Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Stock Short Interest Declines 81.8%

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 19,178 shares, a decrease of 81.8% from the September 30th total of 105,501 shares. Based on an average daily trading volume, of 224,827 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Daiichi Sankyo Trading Up 1.5%

Shares of DSNKY traded up $0.24 during trading hours on Thursday, hitting $16.54. The stock had a trading volume of 241,029 shares, compared to its average volume of 306,324. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $25.69. The firm has a market cap of $30.81 billion, a P/E ratio of 19.23, a P/E/G ratio of 1.90 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The company’s fifty day simple moving average is $17.80 and its 200 day simple moving average is $17.72.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Equities research analysts forecast that Daiichi Sankyo will post 0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

DSNKY has been the subject of several recent analyst reports. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.